We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hyseq and Variagenics Announce Merger

By Biotechdaily staff writers
Posted on 28 Nov 2002
Citing the benefits of integrating their separate assets into a product-focused organization, Hyseq Pharmaceuticals, Inc. (Sunnyvale, CA, USA) and Variagenics, Inc. (Cambridge, MA, USA) have announced an agreement to merge in an exchange of stock that represents a purchase price for Variagenics of around US$55.9 million.

The new company will be headquartered in Sunnyvale, CA, the site of Hyseq's clinical operations and biotherapeutic research and discovery programs. The molecular diagnostics development program of Variagenics will continue in Cambridge, MA. Hyseq's current chairman, Dr. George Rathmann, will assume the chairmanship of the new company's board of directors.

Assets of the two companies include a novel acting thrombolytic, a biotherapeutic drug development pipeline based on human gene sequences, a cancer diagnostics program, and a proprietary SNP database to support molecular diagnostics.

"The new organization will leverage its substantial cash position to support the development of Hyseq's novel thrombolytic called alfimeprase, Variagenics' cancer diagnostics program, and other near-term revenue generating opportunities,” said Dr. Ted W. Love, president and CEO of Hyseq.




Related Links:
Hyseq
Variagenics

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
New
Silver Member
Quality Control Material
Multichem ID-B

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
28 Nov 2002  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
28 Nov 2002  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
28 Nov 2002  |   BioResearch



PURITAN MEDICAL